Latest Insider Transactions at Phreesia, Inc. (PHR)
This section provides a real-time view of insider transactions for Phreesia, Inc. (PHR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Phreesia, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Phreesia, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 13
2022
|
Evan Roberts Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,724
-0.65%
|
$132,272
$28.73 P/Share
|
|
Apr 13
2022
|
Evan Roberts Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,253
+1.26%
|
-
|
|
Apr 13
2022
|
Chaim Indig Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,357
-0.74%
|
$261,996
$28.73 P/Share
|
|
Apr 13
2022
|
Chaim Indig Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,328
+1.44%
|
-
|
|
Mar 26
2022
|
Randy Rasmussen Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
52
-0.04%
|
$1,404
$27.78 P/Share
|
|
Feb 18
2022
|
Chaim Indig Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
78,106
+3.02%
|
$468,636
$6.37 P/Share
|
|
Jan 31
2022
|
Edward L Cahill Director |
BUY
Grant, award, or other acquisition
|
Direct |
280
+0.96%
|
$8,680
$31.19 P/Share
|
|
Jan 31
2022
|
Lainie Goldstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
280
+1.88%
|
$8,680
$31.19 P/Share
|
|
Jan 21
2022
|
Evan Roberts Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+3.38%
|
$50,000
$2.03 P/Share
|
|
Jan 19
2022
|
Randy Rasmussen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,228
-0.86%
|
$71,296
$32.62 P/Share
|
|
Jan 17
2022
|
Chaim Indig Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
39,206
-3.27%
|
$1,372,210
$35.55 P/Share
|
|
Jan 17
2022
|
Evan Roberts Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,743
-0.25%
|
$61,005
$35.55 P/Share
|
|
Jan 17
2022
|
David Linetsky SVP, Life Sciences |
SELL
Payment of exercise price or tax liability
|
Direct |
416
-0.19%
|
$14,560
$35.55 P/Share
|
|
Jan 17
2022
|
Michael J. Davidoff SVP, Payer Business |
SELL
Payment of exercise price or tax liability
|
Direct |
1,231
-1.08%
|
$43,085
$35.55 P/Share
|
|
Jan 17
2022
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
501
-0.71%
|
$17,535
$35.55 P/Share
|
|
Jan 15
2022
|
Chaim Indig Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
18,438
-1.51%
|
$645,330
$35.55 P/Share
|
|
Jan 15
2022
|
Evan Roberts Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,543
-1.36%
|
$334,005
$35.55 P/Share
|
|
Jan 15
2022
|
David Linetsky SVP, Life Sciences |
SELL
Payment of exercise price or tax liability
|
Direct |
4,251
-1.89%
|
$148,785
$35.55 P/Share
|
|
Jan 15
2022
|
Randy Rasmussen Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
849
-0.65%
|
$29,715
$35.55 P/Share
|
|
Jan 15
2022
|
Allison C Hoffman General Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
879
-0.75%
|
$30,765
$35.55 P/Share
|
|
Jan 15
2022
|
Michael J. Davidoff SVP, Payer Business |
SELL
Payment of exercise price or tax liability
|
Direct |
4,211
-3.56%
|
$147,385
$35.55 P/Share
|
|
Jan 15
2022
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
2,364
-3.22%
|
$82,740
$35.55 P/Share
|
|
Jan 14
2022
|
Chaim Indig Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
91,420
+6.98%
|
-
|
|
Jan 14
2022
|
Evan Roberts Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
53,445
+7.09%
|
-
|
|
Jan 14
2022
|
David Linetsky SVP, Life Sciences |
BUY
Grant, award, or other acquisition
|
Direct |
53,445
+19.21%
|
-
|
|
Jan 14
2022
|
Randy Rasmussen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
53,445
+29.01%
|
-
|
|
Jan 14
2022
|
Allison C Hoffman General Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
35,161
+23.09%
|
-
|
|
Jan 14
2022
|
Michael J. Davidoff SVP, Payer Business |
BUY
Grant, award, or other acquisition
|
Direct |
35,161
+22.93%
|
-
|
|
Jan 14
2022
|
Amy Beth Van Duyn SVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
22,503
+23.47%
|
-
|
|
Jan 11
2022
|
Evan Roberts Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
43,750
+6.34%
|
$0
$0.84 P/Share
|
|
Jan 07
2022
|
Chaim Indig Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
84,270
+6.95%
|
$168,540
$2.03 P/Share
|
|
Jan 06
2022
|
David Linetsky SVP, Life Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
30,950
+5.55%
|
$154,750
$5.82 P/Share
|
|
Dec 31
2021
|
Chaim Indig Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
255,000
-19.64%
|
-
|
|
Dec 31
2021
|
Allison C Hoffman General Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
137
+0.17%
|
$4,795
$35.41 P/Share
|
|
Dec 31
2021
|
Randy Rasmussen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
342
+0.44%
|
$11,970
$35.41 P/Share
|
|
Dec 31
2021
|
Michael J. Davidoff SVP, Payer Business |
BUY
Exercise of conversion of derivative security
|
Direct |
6,399
+7.16%
|
$25,596
$4.71 P/Share
|
|
Dec 09
2021
|
Chaim Indig Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+3.71%
|
$100,000
$2.03 P/Share
|
|
Dec 09
2021
|
Evan Roberts Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+7.66%
|
$0
$0.84 P/Share
|
|
Nov 09
2021
|
Randy Rasmussen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,185
-8.54%
|
$524,505
$73.98 P/Share
|
|
Nov 08
2021
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
1,499
-1.06%
|
$112,425
$75.12 P/Share
|
|
Nov 08
2021
|
David Linetsky SVP, Life Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
1,499
+1.05%
|
$5,996
$4.71 P/Share
|
|
Nov 06
2021
|
Randy Rasmussen Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,862
-3.29%
|
$208,926
$73.81 P/Share
|
|
Nov 05
2021
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
3,478
-2.42%
|
$260,850
$75.15 P/Share
|
|
Nov 05
2021
|
David Linetsky SVP, Life Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
3,478
+2.36%
|
$13,912
$4.71 P/Share
|
|
Nov 01
2021
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
5,451
-1.89%
|
$381,570
$70.83 P/Share
|
|
Nov 01
2021
|
David Linetsky SVP, Life Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
5,451
+3.6%
|
$21,804
$4.71 P/Share
|
|
Oct 29
2021
|
Edward L Cahill Director |
BUY
Grant, award, or other acquisition
|
Direct |
124
+0.43%
|
$8,680
$70.54 P/Share
|
|
Oct 29
2021
|
Lainie Goldstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
124
+0.86%
|
$8,680
$70.54 P/Share
|
|
Oct 15
2021
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
5,452
-3.74%
|
$354,380
$65.36 P/Share
|
|
Oct 15
2021
|
David Linetsky SVP, Life Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
5,452
+3.6%
|
$21,808
$4.71 P/Share
|